Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows
Discover how Glaukos’ GLK-321 Phase 2 trial could reshape Demodex blepharitis care through a dropless eyelid-applied treatment.
Pharma & Biotech
Pharma & Biotech
Can Alcon turn baseball fandom into a growth engine for Systane in Canada’s dry eye category?
See how Alcon is using the Toronto Blue Jays to expand Systane’s dry eye reach in Canada and what it means for eye care competition.
Pharma & Biotech
What Cloudbreak Pharma’s Phase 2 FDA meeting reveals about late-stage risk in ophthalmic drug development
Find out how Cloudbreak Pharma’s Phase 2 FDA meeting reshapes late-stage risk for CBT-004 and what it signals for ophthalmic drug development.
Medical Devices & Diagnostics
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.